|
| Target HDAC or HAT | Molecular pathway | Experimental model | Cardiovascular effect | Reference |
|
| ↑ Sirt1 | ↓ TGF-β, Col III, Col I | TAC induced myocardial infraction
In vivo
Ang II-Induced hypertrophy
In vitro | ↓ infract area
↓ fibrosis
↓ hypertrophy | [77] |
| ↑ Sirt1 | ↑ SOD
↑ Bcl2, ↓ Bax | Isolated ischemia-reperfusion model
Ex vivo
TAC induced myocardial infraction
In vivo
Simulated ischemia-reperfusion model
In vitro | Improved post-ischemic cardiac function
↓ myocardial infract size
↓ apoptotic index
↓ oxidative stress
Preserved serum CK activity
↓ LDH serum levels | [42] |
| ↑ Sirt1 | ↑ eNOS
↓ p21 | H2O2-induced endothelial premature senescence
In vitro | ↓ premature senescence
↓ oxidative stress
↓ apoptosis
Preverved NO synthesis | [79] |
| ↑ Sirt1 | ↑ AMPKα
↑ LXR-α
↑ ATP binding cassette transporter 1 | Atherogenic model
In vitro | Antiatherogenic
↓ cellular cholesterol
↑ cholesterol efflux from THP-1 | [78] |
| ↓ p300-HAT | ↓ acetylation of histones 3 and 4 | LPS-induced cardiac hypertrophy
In vivo | ↓ cardiac hypertrophy | [83] |
| ↓ p300-HAT | ↓ TGF-β/Smad2 | High glucose-induced cardiac hypertrophy
In vitro
Streptozotocin-induced cardiac dysfunction
In vivo | ↓ cardiac hypertrophy
↓ extracellular matrix production
↑ diastolic function | [81] |
| ↓ p300-HAT | ↓ GATA4
↓ NF-κB
↓ acetylation of histones 3 and 4 | TAC induced myocardial Infraction
In vivo
PE-induced hypertrophy
In vitro | ↓ LV wall thickness
Preserved systolic function
↓ hypertrophy | [77] |
| ↓ p300-HAT | ↓ Ac-p53
↓ ANF, β-MHC
↓ Bax, Cyt c, caspase 3, and PARP | TAC induced myocardial Infraction
In vivo
Ang II-Induced hypertrophy
In vitro | ↓ hypertrophy
↓ apoptosis | [80] |
| ↓ p300-HAT | ↓ GATA4
↓ p53 | Hypoxia-induced hypertrophy model
In vitro | Stabilized mitochondrial membrane potential
Restored lactate, acetyl-coA pyruvate, and glucose levels | [82] |
|
